左束支起搏与双心室起搏在心力衰竭中的长期结局:HeartSync-LBBP随机临床试验
这项多中心前瞻性随机临床试验纳入200例LVEF≤35%且合并左束支传导阻滞的心力衰竭患者,1:1随机接受左束支起搏(LBBP)或双心室起搏(BiVP)。中位随访36个月显示,LBBP组主要终点(全因死亡或心衰住院)风险显著低于BiVP组(8% vs 28%;HR 0.26;95%CI 0.12-0.57;P<.001),主要由心衰住院减少驱动,全因死亡无显著差异。
要点
- LBBP较BiVP显著降低死亡或心衰住院复合终点风险(HR 0.26)。
- 心衰住院风险显著降低(7.0% vs 28.0%;HR 0.23),全因死亡无显著差异。
- LBBP组超声超反应率更高(55.0% vs 36.0%;P=.007)。
核心结论
- 在LVEF≤35%且合并左束支传导阻滞的心衰患者中,LBBP在降低死亡或心衰住院风险方面优于BiVP。
研究设计与样本
- 多中心、前瞻性、随机临床试验,纳入中国6个中心200例LVEF≤35%且合并左束支传导阻滞的患者,1:1随机接受LBBP或BiVP,中位随访36个月(范围33-39个月)。
主要发现
- 主要终点(全因死亡或心衰住院)LBBP组8% vs BiVP组28%(HR 0.26;95%CI 0.12-0.57;P<.001)。
- 全因死亡两组无显著差异(2.0% vs 5.0%;HR 0.40;95%CI 0.08-2.04;P=.25)。
- 心衰住院LBBP组显著低于BiVP组(7.0% vs 28.0%;HR 0.23;95%CI 0.10-0.52;P<.001)。
- 超声反应率两组相似(86.0% vs 81.0%;P=.34),超反应率LBBP组更高(55.0% vs 36.0%;P=.007)。
- 起搏成功率LBBP组98%、BiVP组94%(P=.28)。
临床怎么用
- 对于LVEF≤35%合并左束支传导阻滞的心衰患者,LBBP可作为BiVP的替代起搏策略以降低心衰住院风险。
局限性
- 研究仅纳入中国6个中心200例患者,样本量有限,结论外推需谨慎。
- 全因死亡事件数较少,两组死亡率差异未达统计学显著。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Left bundle-branch pacing (LBBP) has been proposed as an alternative to biventricular pacing (BiVP) for patients with heart failure with left bundle-branch block (LBBB). However, robust clinical evidence from randomized clinical trials is lacking. OBJECTIVE: To evaluate the long-term clinical outcomes of LBBP and BiVP. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, prospective, randomized clinical trial enrolled 200 patients at 6 centers in China with a left ventricular ejection fraction (LVEF) of 35% or less and LBBB from October 2020 to March 2022. This study was took place from October 2020 to September 2024. These data were analyzed September 2024 to December 2024. INTERVENTIONS: Patients were randomly assigned in a 1:1 ratio to receive either LBBP or BiVP. MAIN OUTCOMES AND MEASURES: The primary end point was the time to death from any cause or heart failure hospitalization (HFH). The secondary end points included all-cause death, HFH, echocardiographic response (absolute increase in LVEF ≥5%), and super response (absolute increase in LVEF ≥15% or improvement of LVEF to ≥50%) rates. RESULTS: Of the 200 included patients, 136 were male and 64 were female. The success rate was 98% in the LBBP group and 94% in the BiVP group (P = .28). The median follow-up duration was 36 (range, 33-39) months. The primary end point of time to death or HFH was significantly lower in the LBBP group compared with BiVP (8% vs 28%; hazard ratio [HR], 0.26; 95% CI, 0.12-0.57; P < .001). There was no significant difference in all-cause mortality between the groups (2.0% vs 5.0%; HR, 0.40; 95% CI, 0.08-2.04; P = .25). However, LBBP significantly reduced the risk of HFH (7.0% vs 28.0%; HR, 0.23; 95% CI, 0.10-0.52; P < .001). The echocardiographic response rates were similar in both groups (86.0% vs 81.0%; P = .34) but the super-response rate was higher in the LBBP group (55.0% vs 36.0%; P < .007). CONCLUSIONS AND RELEVANCE: In this study, LBBP was superior to BiVP in reducing the risk of death or HFH in patients with LBBB and severely reduced LVEF. Further trials are warranted in this patient population. TRIAL REGISTRATION: Chinese Clinical Trial Registry identifier: ChiCTR2000036554.
引用
- Chen, Liu, Li, et al. Long-Term Outcomes of Left Bundle-Branch Pacing vs Biventricular Pacing in Heart Failure: The HeartSync-LBBP Randomized Clinical Trial. JAMA Cardiol. 2026. PMID: 41811342. doi:10.1001/jamacardio.2026.0083
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。